GLP-1s would save employers money in the long term if they were priced at $350 a month or less, the pharmacy juggernaut found.
LAS VEGAS — GLP-1s for weight loss, diabetes and other conditions can save employers and other payers money — if they’re priced at $350 per month or less, according to a new analysis by CVS Health.
The white paper, released Sunday during the HLTH conference in Las Vegas, found that GLP-1s are associated with better health outcomes, fewer hospitalizations and lower medical spending. But at their current sky-high prices, pharmacy spending on GLP-1s swamps any medical savings for plan sponsors, CVS found. Per the Employee Benefit Research Institute, employers typically pay between $617 and $766 a month for GLP-1s.
The goal of the white paper is to pressure drugmakers like Eli Lilly and Novo Nordisk to lower the cost of the popular medications, according to Dr. Amy Compton-Phillips, CVS’ chief medical officer.
“Employers are having to make these Solomon-like decisions. Like, ‘It seems these are good drugs, but if I pay for them, I can’t afford coverage for my employees,’ right? It’s impossible,” Compton-Phillips said in an interview on the sidelines of HLTH.
GLP-1s have been a golden goose for Lilly and Novo, which capture nearly the entire GLP-1 market through products like Zepbound, Mounjaro, Wegovy and Ozempic.
The global market for GLP-1s is expected to reach $190 billion by 2035, $40 billion more than previously estimated, as the market for weight loss drugs rapidly expands, according to Morgan Stanley.
Source link







